Pharmaceutics International Inc. (Pii), a contract development and manufacturing organization (CDMO), has announced a significant expansion of its prefilled syringe (PFS) capabilities with a $3.6 million investment in advanced labeling, fill/finish, and automated visual inspection technologies.
 
This development reflects Pii’s commitment to supporting pharmaceutical and biotech companies with end-to-end, streamlined solutions for drug manufacturing and supply chain efficiency.
 
Driven by the rising demand for prefilled syringe solutions in the pharmaceutical and biotech industries, Pii’s investment includes an Optima syringe labeler and Antares automated visual inspection (AVI) system. These additions enable Pii to offer integrated fill/finish and labeling services for PFS, simplifying the supply chain and reducing the time required to bring critical medicines to market.
 
“With this expansion, Pii strengthens its role as a comprehensive partner, allowing clients to achieve faster time-to-market by managing every step of the PFS process,” said John Fowler, Chief Executive Officer at Pii. “Our streamlined approach will support customers in optimizing both cost and quality, meeting stringent regulatory demands, and ultimately improving patient access to essential therapies.”
 
Pii’s commitment to innovation and patient-centric solutions is central to this investment, aligning with industry trends toward self-administered therapies and ready-to-use delivery formats. By integrating advanced PFS capabilities with a comprehensive quality management system, Pii aims to provide an efficient, reliable manufacturing solution for customers, particularly small and mid-sized pharmaceutical companies striving for rapid clinical trials or market entry.

More Pii News